Publications 2025

Giacoppo D, Gragnano F, Watanabe H, Kimura T, Kang J, Park KW, Kim HS, Pettersen AÅ, Bhatt DL, Pocock S, Mehran R, Valgimigli M (2025)
P2Y₁₂ inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials
BMJ, 389, e082561
DOI 10.1136/bmj-2024-082561, PubMed 40467090

Valgimigli M, Choi KH, Giacoppo D, Gragnano F, Kimura T, Watanabe H, Kim HS, Kang J, Park KW, Pettersen AÅ, Woodward M, Bhatt DL, Calabrò P, Angiolillo DJ, Mehran R, Song YB, Hahn JY (2025)
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis
Lancet, 406 (10508), 1091-1102
DOI 10.1016/S0140-6736(25)01562-4, PubMed 40902613

Publications 2020

Kluge KE, Langseth MS, Bratseth V, Pettersen AÅ, Arnesen H, Tønnessen T, Seljeflot I, Helseth R (2020)
Circulating levels of the terminal complement complex are associated with hypercoagulability in patients with stable coronary artery disease
Thromb Res, 196, 106-108
DOI 10.1016/j.thromres.2020.08.023, PubMed 32853976

Kluge KE, Langseth MS, Opstad TB, Pettersen AÅ, Arnesen H, Tønnessen T, Seljeflot I, Helseth R (2020)
Complement Activation in Association with Markers of Neutrophil Extracellular Traps and Acute Myocardial Infarction in Stable Coronary Artery Disease
Mediators Inflamm, 2020, 5080743
DOI 10.1155/2020/5080743, PubMed 32308555

Publications 2019

Opstad TB, Kalstad AA, Pettersen AÅ, Arnesen H, Seljeflot I (2019)
Novel biomolecules of ageing, sex differences and potential underlying mechanisms of telomere shortening in coronary artery disease
Exp Gerontol, 119, 53-60
DOI 10.1016/j.exger.2019.01.020, PubMed 30684534

Publications 2018

Langseth MS, Opstad TB, Bratseth V, Solheim S, Arnesen H, Pettersen AÅ, Seljeflot I, Helseth R (2018)
Markers of neutrophil extracellular traps are associated with adverse clinical outcome in stable coronary artery disease
Eur J Prev Cardiol, 25 (7), 762-769
DOI 10.1177/2047487318760618, PubMed 29473463

Publications 2016

Opstad TB, Arnesen H, Pettersen AÅ, Seljeflot I (2016)
Combined Elevated Levels of the Proinflammatory Cytokines IL-18 and IL-12 Are Associated with Clinical Events in Patients with Coronary Artery Disease: An Observational Study
Metab Syndr Relat Disord, 14 (5), 242-8
DOI 10.1089/met.2015.0130, PubMed 27058587

Opstad TB, Brusletto BS, Arnesen H, Pettersen AÅ, Seljeflot I (2016)
Cigarette smoking represses expression of cytokine IL-12 and its regulator miR-21-An observational study in patients with coronary artery disease
Immunobiology, 222 (2), 169-175
DOI 10.1016/j.imbio.2016.10.007, PubMed 27765464

Publications 2015

Pettersen AA, Arnesen H, Seljeflot I (2015)
A brief review on high on-aspirin residual platelet reactivity
Vascul Pharmacol, 67-69, 6-9
DOI 10.1016/j.vph.2015.03.018, PubMed 25869498

Publications 2014

Opstad TB, Arnesen H, Pettersen AÅ, Seljeflot I (2014)
The MMP-9 -1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease
PLoS One, 9 (9), e106816
DOI 10.1371/journal.pone.0106816, PubMed 25191702

Publications 2013

Opstad TB, Pettersen AÅ, Arnesen H, Seljeflot I (2013)
The co-existence of the IL-18+183 A/G and MMP-9 -1562 C/T polymorphisms is associated with clinical events in coronary artery disease patients
PLoS One, 8 (9), e74498
DOI 10.1371/journal.pone.0074498, PubMed 24040261

Publications 2012

Bratseth V, Pettersen AÅ, Opstad TB, Arnesen H, Seljeflot I (2012)
Markers of hypercoagulability in CAD patients. Effects of single aspirin and clopidogrel treatment
Thromb J, 10 (1), 12
DOI 10.1186/1477-9560-10-12, PubMed 22883224

Njerve IU, Pettersen AÅ, Opstad TB, Arnesen H, Seljeflot I (2012)
Fractalkine and its receptor (CX3CR1) in patients with stable coronary artery disease and diabetes mellitus
Metab Syndr Relat Disord, 10 (6), 400-6
DOI 10.1089/met.2012.0052, PubMed 22897138

Pettersen AÅ, Arnesen H, Opstad TB, Bratseth V, Seljeflot I (2012)
Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease
Thromb Res, 130 (3), 424-8
DOI 10.1016/j.thromres.2012.06.016, PubMed 22795340

Pettersen AÅ, Seljeflot I, Abdelnoor M, Arnesen H (2012)
High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)
J Am Heart Assoc, 1 (3), e000703
DOI 10.1161/JAHA.112.000703, PubMed 23130135

Publications 2011

Opstad TB, Pettersen AÅ, Arnesen H, Seljeflot I (2011)
Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study
Cardiovasc Diabetol, 10, 110
DOI 10.1186/1475-2840-10-110, PubMed 22141572

Opstad TB, Pettersen AA, Weiss TW, Akra S, Øvstebø R, Arnesen H, Seljeflot I (2011)
Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease
Clin Chim Acta, 413 (1-2), 113-20
DOI 10.1016/j.cca.2011.09.004, PubMed 21963461

Pettersen AA, Arnesen H, Opstad TB, Seljeflot I (2011)
The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
Thromb J, 9, 4
DOI 10.1186/1477-9560-9-4, PubMed 21426546

Publications 2010

Opstad TB, Pettersen AA, Bratseth V, Arnesen H, Seljeflot I (2010)
The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease
Pathophysiol Haemost Thromb, 37 (2-4), 98-103
DOI 10.1159/000327491, PubMed 21555871

Opstad TB, Pettersen AA, Weiss T, Arnesen H, Seljeflot I (2010)
Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes
Thromb J, 8, 7
DOI 10.1186/1477-9560-8-7, PubMed 20444258

Publications 2006

Solheim S, Pettersen AA, Arnesen H, Seljeflot I (2006)
No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease
Thromb Haemost, 96 (5), 660-4
DOI 10.1160/TH06-06-0337, PubMed 17080224

Publications 2004

Pettersen AA, Müller C, Bendz B, Halvorsen S, Eritsland J, Brekke M, Mangschau A (2004)
[Reduction of myocardial infarction size after primary percutaneous coronary intervention]
Tidsskr Nor Laegeforen, 124 (10), 1387-9
PubMed 15195177

Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H (2004)
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design
Scand Cardiovasc J, 38 (6), 353-6
DOI 10.1080/14017430410024324, PubMed 15804802